Amgen's Blincyto on path to broader ALL indication
This article was originally published in Scrip
Executive Summary
Amgen has a broader indication for its acute lymphocytic leukemia (ALL) treatment Blincyto (blinatumomab) in its sights after top-line Phase II data looked positive in adults with relapsed or refractory Philadelphia chromosome-positive (Ph+) B-cell precursor ALL.